Cojocel C, Dociu N, Maita K, Sleight S D, Hook J B
Toxicol Appl Pharmacol. 1983 Mar 30;68(1):96-109. doi: 10.1016/0041-008x(83)90358-7.
Gentamicin and other aminoglycoside antibiotics in high doses may produce proteinuria and other signs of nephrotoxicity. Proteinuria may result from general renal damage or may reflect alterations in specific steps in the renal handling of proteins. To distinguish between these two possibilities, experiments were designed to quantify the effects of nephrotoxic doses of several aminoglycosides on the renal handling of proteins in the isolated perfused rat kidney with the cationic low-molecular-weight protein lysozyme as a representative protein. Each aminoglycoside was administered ip to male Wistar rats (30 mg/kg/day) for 7 days. Lysozyme and 125I-lysozyme were added to the perfusate to achieve a lysozyme perfusate concentration of about 100 mg/liter. Clearances of inulin and lysozyme, release of tyrosine and trichloroacetic acid-soluble radioactive metabolites into the perfusate, and the glomerular sieving coefficient of lysozyme were determined. Scanning and transmission electron microscopy indicated that gentamicin and tobramycin decreased the number and diameter of the endothelial fenestrae of the glomerular capillaries. Concurrently, gentamicin and tobramycin decreased the glomerular sieving coefficient of lysozyme from 0.8 to 0.6 and 0.5, respectively. Netilmicin did not affect the percentage reabsorption of lysozyme whereas gentamicin and tobramycin decreased lysozyme reabsorption from 71.7 to 35.4 and 34.4% of the filtered load, respectively. Lysozyme degradation, estimated by the release of tyrosine into the perfusate during a 150-min perfusion period, was decreased from a control value of 12 mumol/liter to 4.43 and 4.65 mumol/liter in kidneys from rats treated with gentamicin and tobramycin, respectively. This study demonstrates that polycationic aminoglycosides may affect several processes involved in renal handling of lysozyme including glomerular permeability, tubular reabsorption, and intracellular proteolytic degradation.
高剂量的庆大霉素和其他氨基糖苷类抗生素可能会产生蛋白尿及其他肾毒性迹象。蛋白尿可能源于一般性肾损伤,也可能反映肾脏处理蛋白质特定步骤的改变。为区分这两种可能性,设计了实验,以阳离子低分子量蛋白质溶菌酶作为代表性蛋白质,来量化几种氨基糖苷类肾毒性剂量对离体灌注大鼠肾脏蛋白质处理的影响。每种氨基糖苷类药物经腹腔注射给予雄性Wistar大鼠(30毫克/千克/天),持续7天。将溶菌酶和125I-溶菌酶添加到灌注液中,使溶菌酶灌注液浓度达到约100毫克/升。测定菊粉和溶菌酶的清除率、酪氨酸释放到灌注液中的量以及三氯乙酸可溶性放射性代谢物的量,还有溶菌酶的肾小球滤过系数。扫描电子显微镜和透射电子显微镜显示,庆大霉素和妥布霉素可减少肾小球毛细血管内皮窗孔的数量和直径。同时,庆大霉素和妥布霉素分别将溶菌酶的肾小球滤过系数从0.8降至0.6和0.5。奈替米星不影响溶菌酶的重吸收百分比,而庆大霉素和妥布霉素分别将溶菌酶重吸收从滤过负荷的71.7%降至35.4%和34.4%。通过在150分钟灌注期内酪氨酸释放到灌注液中的量来估算的溶菌酶降解,在接受庆大霉素和妥布霉素治疗的大鼠肾脏中,分别从对照值12微摩尔/升降至4.43微摩尔/升和4.65微摩尔/升。本研究表明,聚阳离子氨基糖苷类药物可能会影响肾脏处理溶菌酶所涉及的多个过程,包括肾小球通透性、肾小管重吸收和细胞内蛋白水解降解。